177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer

• Status: Recruiting
• Trial end date: 2024-12-01

Summary

The purpose of this study is to test the effectiveness of the experimental drug, 177Lu-J591 in combination with ketoconazole and hydrocortisone against prostate cancer.

• Phase: Phase 2

Details

• Lead Sponsor: Weill Medical College of Cornell University
• Collaborator: United States Department of Defense
• Treatments: Antibodies; Antibodies, Monoclonal; Cortisol succinate; Hydrocortisone; Hydrocortisone 17-butyrate 21-propionate; Hydrocortisone acetate; Ketoconazole